宜明昂科(01541.HK)核心产品替达派西普III期临床试验方案获批

阿斯达克财经04-18

宜明昂科－Ｂ(01541.HK) 公布，获中国国家药监局对IMM01(替达派西普)与替雷利珠单抗联用治疗程序性细胞死亡蛋白抑制剂治疗后复发或病情有所进展的复发性或难治性经典霍奇金淋巴瘤进行III期临床试验方案的批准。集团的核心产品IMM01是创新靶向分化簇47的分子。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2428254243?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg","is_english":false,"pubTime":"2024-04-18 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428254243","market":"hk","top_or_hot":-1,"title":"宜明昂科(01541.HK)核心产品替达派西普III期临床试验方案获批","media":"阿斯达克财经","content":"<div>\n<p>宜明昂科－Ｂ(01541.HK) 公布，获中国国家药监局对IMM01(替达派西普)与替雷利珠单抗联用治疗程序性细胞死亡蛋白抑制剂治疗后复发或病情有所进展的复发性或难治性经典霍奇金淋巴瘤进行III期临床试验方案的批准。集团的核心产品IMM01是创新靶向分化簇47的分子。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343060/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>宜明昂科(01541.HK)核心产品替达派西普III期临床试验方案获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n宜明昂科(01541.HK)核心产品替达派西普III期临床试验方案获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 00:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343060/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>宜明昂科－Ｂ(01541.HK) 公布，获中国国家药监局对IMM01(替达派西普)与替雷利珠单抗联用治疗程序性细胞死亡蛋白抑制剂治疗后复发或病情有所进展的复发性或难治性经典霍奇金淋巴瘤进行III期临床试验方案的批准。集团的核心产品IMM01是创新靶向分化簇47的分子。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343060/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343060/latest-news/AAFN","article_id":"2428254243","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428254243","pubTimestamp":1713371640,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"宜明昂科－Ｂ(01541.HK) 公布，获中国国家药监局对IMM01(替达派西普)与替雷利珠单抗联用治疗程序性细胞死亡蛋白抑制剂治疗后复发或病情有所进展的复发性或难治性经典霍奇金淋巴瘤进行III期临床试验方案的批准。集团的核心产品IMM01是创新靶向分化簇47的分子。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","III":"信息服务","BK1583":"高瓴概念","01541":"宜明昂科-B","BK4134":"信息科技咨询与其它服务","03347":"泰格医药"},"translate_title":"The Phase III clinical trial protocol of Tedapacept, the core product of Yiming Angke (01541. HK), was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1,"03347":1,"III":1},"content_text":"宜明昂科－Ｂ(01541.HK) 公布，获中国国家药监局对IMM01(替达派西普)与替雷利珠单抗联用治疗程序性细胞死亡蛋白抑制剂治疗后复发或病情有所进展的复发性或难治性经典霍奇金淋巴瘤进行III期临床试验方案的批准。集团的核心产品IMM01是创新靶向分化簇47的分子。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428254243"}